Skip to main content
CUE logo

Cue Biopharma, Inc.

CUENASDAQHealthcareBiotechnology

$18.45Today:- (-)1Y +2320.86%

As of Oct 26, 2026 close

Market cap
$116.99M
P/E (TTM)
-
Forward P/E
-
Dividend yield
-
52-week range
$0.23$45.50
Volume (live)
-
Avg. volume (3M)
365.19K

Cue Biopharma (CUE) Income Statement

Cue Biopharma reported revenue of $27.47M in fiscal 2025 (fiscal year ended Dec 31, 2025), up 195.7% from $9.29M a year earlier. Cue Biopharma posted a net loss of $26.60M, compared with a net loss of $40.67M a year earlier. Gross margin was 100.0% and operating margin -96.6%. In the most recent quarter, Q2 fiscal 2026 (ended Jun 30, 2026), revenue was $7.88M, up 166.7% from the same quarter a year earlier.

Cue Biopharma Income Statement Analysis

Values in millions USD

Scroll to see more
Cue Biopharma, Inc. income statement - Annual data in millions USD
BreakdownFY 2025FY 2024FY 2024FY 2023FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
Period endingDec 2025Mar 2025Dec 2024Mar 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017
Revenue & Gross Profit
Revenue27.479.299.295.495.491.2514.943.153.461.140.00
Cost of Revenue0.000.0032.9038.1040.8035.3041.3533.5527.4928.540.42
Gross Profit27.479.299.29-32.615.491.2514.94-30.39-24.03-27.40-0.42
Operating Expenses
Research & Development37.7436.3036.3040.8040.8038.5841.3533.5527.4928.5418.90
Selling, General & Administrative16.2414.5914.5916.6816.6819.4517.3114.6512.7411.304.33
Operating Expenses53.9950.7950.8819.5457.6454.4758.6514.6512.7439.8423.23
Operating Income-26.52-41.50-41.59-52.15-52.15-53.23-43.71-45.04-36.77-38.70-23.23
Other Income/Expense
Interest Income0.811.621.622.662.660.930.050.460.420.380.00
Interest Expense0.360.800.801.25-1.25-0.710.000.000.000.000.00
Other Income/Expense0.420.830.091.421.420.220.050.460.480.540.00
Income
Income Before Tax-26.10-40.67-40.67-50.73-50.73-53.01-43.67-44.58-36.29-38.16-23.23
Income Tax Expense0.500.00-0.00-0.000.500.210.410.830.00
Net Income-26.60-40.67-40.67-50.73-50.73-53.01-44.16-44.78-36.70-38.98-23.23
Net Income - Continuous Operations-26.60-40.67-40.67-50.73-50.73-53.01-44.16-44.78-36.70-38.98-23.23
Net Income - Discontinued Operations-----------
EBITDA-22.27-37.53-37.53-46.05-51.44-52.58-42.45-43.99-35.96-37.94-22.81
EBIT-25.75--39.88--51.99-53.50-43.71-45.04---
Depreciation & Amortization3.482.352.353.440.560.921.261.060.810.760.42
Earnings Per Share
Basic EPS-8.00-22.00-22.00-33.00-33.00-45.00-42.00-47.00-50.00-58.00-34.00
Diluted EPS-8.00-22.00-22.00-33.00-33.00-45.00-42.00-47.00-50.00-58.00-34.00
Basic Shares Outstanding3.161.881.881.531.531.191.040.960.730.670.69
Diluted Shares Outstanding3.161.881.881.531.531.191.040.960.730.670.69

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Cue Biopharma Financial Statements

What was Cue Biopharma's revenue in fiscal 2025?

Cue Biopharma reported revenue of $27.47M in fiscal 2025 (fiscal year ended Dec 31, 2025). That was up 195.7% from $9.29M a year earlier.

Is Cue Biopharma profitable?

No. Cue Biopharma reported a net loss of $26.60M in fiscal 2025. In fiscal 2024 it lost $40.67M.

What is Cue Biopharma's operating margin?

Cue Biopharma's operating income was −$26.52M on revenue of $27.47M in fiscal 2025, an operating margin of -96.6%, compared with -446.9% a year earlier.

What is net profit margin?

Net profit margin is net income divided by revenue. It shows how much of each dollar of sales a company keeps as profit after all costs, interest and taxes. Full definition